Will Korean bio stocks rebound as MSCI includes Celltrion, Viromed, HLB?
기사승인 2018.05.16 11:25:14
Marian Chu yjc@docdocdoc.co.kr
- 1Device/ICT‘Physicians’ ability to analyze big data, use AI getting crucial’
- 2PharmaPfizer’s generic business turn ‘disastrous’ amid cancer controversy
- 3Life science‘Radon causes lung cancer; some sanitary pads might be harmful’
- 4PolicyGrisly murder reignites debate over leniency on ‘mentally, physically weak’
- 5PolicyWHO director praises Korea’s separation of drug prescribing, dispensing
- 6Device/ICTPhillip Morris launches next generation heat-not-burn cigarettes
- 7PharmaBayer’s blood thinner wins broader indication for coronary artery disease
set_C1
